William Blair Starts Achaogen (AKAO) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St edges higher with earnings in focus; chip stocks retreat
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices rise as hostilities worsen in the Middle East
- ASML capacity upgrade soothes AI chip bottleneck fears
Cowen Starts Achaogen (AKAO) at Outperform
April 8, 2014 8:08 AM EDTCowen initiated coverage on Achaogen (NASDAQ: AKAO) with an Outperform rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Achaogen click here. For more ratings news on Achaogen click here.
Shares of Achaogen closed at $12.89 yesterday.
... MoreCredit Suisse Starts Achaogen (AKAO) at Outperform
April 7, 2014 7:31 AM EDTCredit Suisse initiated coverage on Achaogen (NASDAQ: AKAO) with an Outperform rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Achaogen click here. For more ratings news on Achaogen click here.
Shares of Achaogen closed at $14.15 yesterday.
... MoreNeedham & Company Starts Achaogen (AKAO) at Buy
April 7, 2014 7:17 AM EDTNeedham & Company initiates coverage on Achaogen (NASDAQ: AKAO) with a Buy rating and a price target of $21.00.
Analyst Alan Car comments, "Lead drug plazomicin is under development for the treatment of infections caused by Carbapenem-Resistant Enterobacteriaceae (CRE). A Phase 3 trial... More
